PubMed Health⌕ Search

Biomedical subjects

Y Machida

Publications and source records attributed to Y Machida.

At least 199 records · Page 11Linked to original sources

Gel ointment of verapamil for percutaneous absorption.

A gel ointment of verapamil designed for systemic action by transdermal absorption was prepared. The amount of drug released in vitro decreased progressively when increasing amounts (from 20 to 50%) of ethanol-propylene glycol (2:1, v/v) were incorporated into the ointment. Transdermal absorption of the drug in vivo was studied in rats. Verapamil was found in the systemic circulation, and plasma drug levels were maintained at a plateau for 12 hours after application. The effect of two additives on absorption was also examined. Azone, a cycloheptanone derivative, increased plasma levels of verapamil up to tenfold, the effect being greatly dependent on the amount of alcohols in the formulation. Isopropyl myristate did not influence systemic absorption, but it effectively increased absorption into skin. We conclude that the gel ointment can be used for transdermal drug delivery when an adequate absorption promoter is added.

Administration, Cutaneous↗

Sustained release tablets based on chitosan and carboxymethylcellulose sodium.

Chitosan and mixtures of chitosan with carboxymethylcellulose sodium (CMC-Na) were examined as vehicles for sustained release tablets of water-insoluble drugs. Prednisolone (PDS) was selected as a model of a water-insoluble drug for this study. Sustained release of PDS from tablets prepared by direct compression of chitosan and CMC-Na was demonstrated in model JP X fluids. Furthermore, the release rate of PDS could be controlled by changing the relative amounts of chitosan and CMC-Na, or the amount of PDS in the tablets, and by certain extra additives. Such chitosan/CMC-Na mixtures are a promising basis in the design of sustained release dosage forms of water-insoluble drugs.

Carboxymethylcellulose Sodium↗

Enhanced percutaneous absorption of homogenized tolnaftate/beta-cyclodextrin polymer ground mixture.

The absorption of tolnaftate after external application of tolnaftate-cyclodextrin polymer homogenized ground mixtures was investigated in comparison with that of tolnaftate alone and non-homogenized mixtures. To evaluate their percutaneous absorption, samples were applied to the shaved back skin of mice. It was found that homogenized ground mixture samples showed the highest level of percutaneous absorption, and also resulted in the highest blood level concentrations.

Animals↗

Preparation of bovine serum albumin nanospheres as drug targeting carriers.

Bovine serum albumin nanospheres (BSA-NS) of mean diameter about 170 nm were prepared by means of the tanning method with glutaraldehyde, and their efficacy as drug targeting carriers was evaluated. To gain insight of biodegradability, BSA microspheres (BSA-MS) were first administered to rats and their distributions in the lungs and liver were observed by a scanning electron microscope. A large amount of BSA-MS was found in the lungs and their surface was slightly degraded at 1 week after the administration. For investigating biocompatibility, the weight increase of the spleen and liver was measured after the administration of the BSA-NS to mice. The spleen weight of the group receiving BSA-NS was equivalent to that of the control group, though the liver weight was significantly increased. It was observed that conjugates of BSA-NS with antibody selectively concentrated on the surface of Sepharose beads which were coated with antigen.

Animals↗

Enhancement of bioavailability of cinnarizine from its beta-cyclodextrin complex on oral administration with DL-phenylalanine as a competing agent.

The present investigation is concerned with an improvement of the bioavailability of cinnarizine by administering its beta-cyclodextrin complex together with another compound which competes with the beta-cyclodextrin molecule in complex formation in aqueous solution (competing agent). The bioavailability of cinnarizine on oral administration of the cinnarizine-beta-cyclodextrin inclusion complex was enhanced by the simultaneous administration of DL-phenylalanine as a competing agent, e.g., the AUC was 1.9 and 2.7 times as large as those of the cinnarizine-beta-cyclodextrin complex alone and cinnarizine alone, respectively. The enhancement of AUC and Cmax completely depended on the dose of DL-phenylalanine. It was found from these results that DL-phenylalanine acted as a competing agent in the GI tract and the minimum effective dose required of DL-phenylalanine might be 1 g for 50 mg of cinnarizine in the cinnarizine-beta-cyclodextrin complex. Evaluating the competing effect of DL-phenylalanine in vitro using an absorption simulator, it was found that the decreased penetration rate of cinnarizine through the artificial lipid barrier with addition of beta-cyclodextrin was restored with the addition of DL-phenylalanine.

Administration, Oral↗

Intranasal administration of beta-interferon in rabbits.

beta-Interferon (IFN) administered intranasally in solution or as a powder without surfactants was not absorbed in rabbits. However, absorption occurred after the addition of surfactants (non-ionic, anionic and amphoteric). Maximum concentrations of IFN in plasma were dependent on the surfactant used, sodium glycocholate being the most effective. Total absorption of IFN following nasal administration with sodium glycocholate was 2.2% of that following intravenous administration.

Administration, Intranasal↗

Use of chitosan and hydroxypropylchitosan in drug formulations to effect sustained release.

This study was an attempt to develop implantable sustained release forms of drugs, based on formulations containing chitosan, a biodegradable polymer from a natural source, and hydroxypropylchitosan (HP-chitosan), its water-soluble derivative. The possibilities were explored using uracil as a model for anticancer drugs. Enzymatic degradation of chitosan and HP-chitosan was first confirmed in vitro (using lysozyme) and in vivo by implanting both materials subcutaneously into the backs of rats. Then, using an in vitro dissolution test, we found that the release rate of uracil from chitosan membranes could be altered by the addition of HP-chitosan. Film- and stick-type implantable dosage forms of chitosan containing uracil were prepared by the 'Extrusion-in-Air' method. These gave rise to sustained release of uracil in vitro and in vivo. We conclude that chitosan and HP-chitosan have a potential as biocompatible and biodegradable vehicles in the preparation of implantable sustained release dosage forms of anticancer drugs.

Chemical Phenomena↗

Comparison of the metabolism of diltiazem following percutaneous, subcutaneous, oral and intravenous administration.

The metabolism of diltiazem hydrochloride following percutaneous administration was compared with that following administration orally and by injection, to ascertain possible advantages in the percutaneous administration of ionizable, water-soluble drugs. The various routes of administration gave rise to markedly differing ratios of diltiazem and deacetylated diltiazem in plasma. The ratio of the AUC values for the two substances was 0.3 (intact skin) and 0.5 (stripped skin) following percutaneous administration, 0.2 following injection, and 0.8 following oral administration of diltiazem. Our results suggest that metabolism may be reduced in routes of administration that lead to very rapid drug absorption and/or rapid clearance from blood. HPLC chromatograms of plasma showed that the number and amounts of metabolites were less when diltiazem was given percutaneously rather than orally.

Administration, Cutaneous↗